Enanta Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also con...
Enanta Pharma announces top-line results for EDP-323 in phase 2a human challenge study
Enanta Pharmaceuticals announced positive phase 2a results for EDP-323, an RSV L-protein inhibitor, showing 85-87% reduction in viral load, 97-98% in infectious viral load, and 66-78% in symptom scores compared to placebo. EDP-323, with Fast Track designation, aims to be a once-daily oral treatment for RSV, addressing a significant need for effective treatments.
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
J&J's Talvey shows promise in multiple myeloma trials; FDA advisory committee votes against cancer immunotherapy use in certain digestive tract cancers; AbbVie's acquisition of Cerevel Therapeutics yields positive Parkinson's drug results; Roche's Gazyva succeeds in lupus nephritis Phase 3 study; Biogen terminates agreement with Sage Therapeutics over failed essential tremor drug; Enanta Pharmaceuticals' EDP-323 shows rapid antiviral effect against RSV.
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase
Enanta Pharmaceuticals announced positive Phase 2a results for EDP-323, showing significant reductions in RSV viral load and symptoms, with favorable safety and tolerability.
© Copyright 2024. All Rights Reserved by MedPath